Integrated Technologies to Accelerate Process Intensification for Viral Vaccine Manufacturing

With the increasing world-wide demand for viral-based vaccines (VBVs) against the coronavirus, faster development times are required to progress VBVs more rapidly into clinical development and then to market. To meet these challenges, vaccine manufacturers are adopting strategies such as process intensification. To facilitate process intensification of VBVs, an integrated portfolio of technologies developed by Sartorius is detailed in this whitepaper.